Efficacy of encorafenib and cetuximab therapy in a young patient with a rare concomitant KRAS and BRAF mutation in primary rectal cancer and wild-type KRAS status in metastases: A case report and literature review

Efficacy of encorafenib and cetuximab therapy in a young patient with a rare concomitant KRAS and BRAF mutation in primary rectal cancer and wild-type KRAS status in metastases: A case report and literature review

The presence of activating somatic mutations in the KRAS and NRAS oncogenes is a negative predictor of treatment with the anti-epidermal growth factor receptor (EGFR) monoclonal antibody in colorectal cancer. The BRAF oncogene also plays an important role in carcinogenesis, and, in colorectal cancer...

Full description

Bibliographic Details
Main Authors: Michal Eid, Martina Jelínková, Jiří Šána, Ondřej Slabý
Format: Article
Language:English
Published: Elsevier 2022-12-01
Series:Current Problems in Cancer: Case Reports
Subjects:
Colorectal cancer
KRAS
BRAF
Comprehensive genomic profiling
Case report
Online Access:http://www.sciencedirect.com/science/article/pii/S2666621922000710

Similar Items

Similar Items